135 related articles for article (PubMed ID: 31533096)
1. Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting.
Giordano G; Cutuli MA; Lucchesi A; Magnifico I; Venditti N; Vergalito F; Gasperi M; Di Marco R
Acta Haematol; 2020; 143(2):155-162. PubMed ID: 31533096
[TBL] [Abstract][Full Text] [Related]
2. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
3. Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.
Riccio E; Sabbatini M; Capuano I; Pellegrino AM; Petruzzelli LA; Pisani A
BMC Nephrol; 2020 Feb; 21(1):57. PubMed ID: 32087684
[TBL] [Abstract][Full Text] [Related]
4. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
5. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
6. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
7. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial.
Cazzola M; Ponchio L; Beguin Y; Rosti V; Bergamaschi G; Liberato NL; Fregoni V; Nalli G; Barosi G; Ascari E
Blood; 1992 Jan; 79(1):29-37. PubMed ID: 1728318
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants.
Pollak A; Hayde M; Hayn M; Herkner K; Lombard KA; Lubec G; Weninger M; Widness JA
Pediatrics; 2001 Jan; 107(1):78-85. PubMed ID: 11134438
[TBL] [Abstract][Full Text] [Related]
10. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
[TBL] [Abstract][Full Text] [Related]
11. Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.
Chen L; Jiang H; Gao W; Tu Y; Zhou Y; Li X; Zhu Z; Jiang Q; Zhan H; Yu J; Fu C; Gao Y
BMJ Open; 2016 Oct; 6(10):e012231. PubMed ID: 27855097
[TBL] [Abstract][Full Text] [Related]
12. [Erythropoietin treatment of anemia associated with multiple myeloma (MM) and myelodysplastic syndrome (MDS)].
Qiao ZH
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):122-4. PubMed ID: 8223121
[TBL] [Abstract][Full Text] [Related]
13. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Musch E; Malek M; Chrissafidou A
Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
[TBL] [Abstract][Full Text] [Related]
14. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.
Terpos E; Mougiou A; Kouraklis A; Chatzivassili A; Michalis E; Giannakoulas N; Manioudaki E; Lazaridou A; Bakaloudi V; Protopappa M; Liapi D; Grouzi E; Parharidou A; Symeonidis A; Kokkini G; Laoutaris NP; Vaipoulos G; Anagnostopoulos NI; Christakis JI; Meletis J; Bourantas KL; Zoumbos NC; Yataganas X; Viniou NA;
Br J Haematol; 2002 Jul; 118(1):174-80. PubMed ID: 12100145
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
Cermák J
Hemoglobin; 2006; 30(1):105-12. PubMed ID: 16540422
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study.
Koutroubakis IE; Karmiris K; Makreas S; Xidakis C; Niniraki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):421-5. PubMed ID: 16538115
[TBL] [Abstract][Full Text] [Related]
17. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
19. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
20. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
